Acura Pharmaceuticals traded at $0.05 this Friday February 3rd, decreasing $0 or 0 percent since the previous trading session. Looking back, over the last four weeks, Acura Pharmaceuticals lost 0 percent. Over the last 12 months, its price fell by 89.53 percent. Looking ahead, we forecast Acura Pharmaceuticals to be priced at 0.05 by the end of this quarter and at 0.04 in one year, according to Trading Economics global macro models projections and analysts expectations.

Stock Price
Daily Change

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Peers Price Day Year
Shionogi 6,207.00 14.00 0.23% -19.95%
AcelRx Pharmaceuticals 2.08 -0.12 -5.45% 379.93%
Acura Pharmaceuticals 0.05 0 0% -89.53%
Intra Cellular Therapies 48.92 -0.82 -1.65% 0.41%
J&J 164.61 -0.93 -0.56% -4.09%
Nektar Therapeutics 3.09 0.09 3.00% -70.46%
Pfizer 44.06 -0.28 -0.63% -16.87%
Rigel Pharmaceuticals 1.79 0.02 1.13% -27.82%
Sun Pharmaceuticals 1,024.10 16.50 1.64% 14.56%
Teva Pharmaceutical Industries Ltd 3,605.00 -6.00 -0.17% 32.88%
Xeris Pharmaceuticals Inc 1.18 -0.08 -6.35% -45.12%

Indexes Price Day Year
USND 12007 -193.86 -1.59% -14.83%

Acura Pharmaceuticals
Acura Pharmaceuticals, Inc. is a drug delivery company that is engaged in the research, development and commercialization of technologies and products intended to address safe use of medications. The Company has discovered and developed approximately three platform technologies, which can be used to develop multiple products. The Company's Oxaydo Tablets (oxycodone HCl, CII), which utilizes the Aversion Technology, is an approved and immediate-release (IR) oxycodone product in the United States. The Company's Impede technology products include Nexafed and Nexafed Sinus Pressure + Pain. Its deterrent technology is Limitx, which is designed to retard the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The Company's Aversion and Limitx technologies are intended to address methods associated with opioid and its Impede technology is directed at the extraction and conversion of pseudoephedrine tablets into methamphetamine.